← 返回专利悬崖列表
CAS 75-16-1
Methylmagnesium bromideBromo(methyl)magnesium
登记编号：(IX)101438-68-a、(XV)101438-70-b、(III)700647-1-a、(XV)909096-1-b、(II)1058685-1-a
应用背景（按来源药适应症）
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate胰腺癌紫杉醇非小细胞肺癌紫杉醇霍奇金病紫杉醇精原细胞瘤紫杉醇卵巢癌紫杉醇乳腺癌紫杉醇蠕形螨性睑缘炎洛替拉纳螨虫感染洛替拉纳莱姆病洛替拉纳酒渣鼻洛替拉纳睑板腺功能障碍洛替拉纳非小细胞肺癌伊鲁阿克非小细胞肺癌舒沃替尼B-细胞淋巴瘤舒沃替尼非霍奇金淋巴瘤舒沃替尼
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C · 观察 / 贸易 | - |
| 紫杉醇Paclitaxel | Tier B · 提前布局 | - |
| 洛替拉纳Lotilaner | Tier C · 观察 / 贸易 | - |
| 伊鲁阿克Iruplinalkib | Tier C · 观察 / 贸易 | - |
| 舒沃替尼Sunvozertinib | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
(3S,4aR,6R,11S,12aS)-3-Bromo-9,12a,13,13-tetramethyl-11-[(triethylsilyl)oxy]-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(3S,4aR,6R,12aR)-3-Bromo-9,12a,13,13-tetramethyl-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(4aS,6R,11S,12aS)-9,12a,13,13-Tetramethyl-11-[(triethylsilyl)oxy]-4a,6,7,11,12,12a-hexahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(4aS,6R,12aS)-9,12a,13,13-Tetramethyl-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→1,1-Dibromo-2,2,3,3-tetramethylcyclopropane→(4aS,6R,12aS)-9,12a,13,13-Tetramethyl-2,3,6,7,8,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5(1H,4aH)-dione→(Vinyl)magnesium bromide→1,1,2,2-Tetramethylethylene→2-Hydroxy-2-methylbutanoic acid→2-Propen-1-one→3-(3-Isopropenyl-4-methyl-3-pentenyl)-2-cyclohexen-1-one→3-Bromo-2,4-dimethylpenta-1,3-diene→3-Ethenylcyclohex-2-en-1-one→3-Ethoxy-2-cyclohexen-1-one→Aluminum trimethanide→Methylmagnesium bromide→Bromoform→Trimethyl([(3S)-3-methyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]cyclohex-1-en-1-yl]oxy)silane→(2beta,4alpha,10beta,13alpha)-10-[(Triethylsilyl)oxy](2-~2~H)taxa-5,11-diene-2,4,13-triol→(2S,3S)-2,3-Dimethyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]-2-(prop-2-enoyl)cyclohexan-1-one→(2S,3S)-3-Methyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]-2-(prop-2-enoyl)cyclohexan-1-one
(aS)-(-)-1,1'-Bi-2-naphthol→(aS)-[1,1'-Binaphthalene]-2,2'-diyl bis(trifluoromethanesulfonate)→Methylmagnesium bromide→(aS)-2,2'-Dimethyl-1,1'-binaphthalene→(aS)-4-tert-Butyl-4,5-dihydro-3H-4lambda5-dinaphtho[2,1-c:1',2'-e]phosphepine-4-thione→(aS)-(4R,4'R)-4,4'-Di-tert-butyl-4,4',5,5'-tetrahydro-3H,3'H-[3,3'-bi-4lambda5-dinaphtho[2,1-c:1',2'-e]phosphepine]-4,4'-dithione
(3S,4aR,6R,11S,12aS)-3-Bromo-9,12a,13,13-tetramethyl-11-[(triethylsilyl)oxy]-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(3S,4aR,6R,12aR)-3-Bromo-9,12a,13,13-tetramethyl-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(4aS,6R,11S,12aS)-9,12a,13,13-Tetramethyl-11-[(triethylsilyl)oxy]-4a,6,7,11,12,12a-hexahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(4aS,6R,12aS)-9,12a,13,13-Tetramethyl-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→1,1-Dibromo-2,2,3,3-tetramethylcyclopropane→(4aS,6R,12aS)-9,12a,13,13-Tetramethyl-2,3,6,7,8,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5(1H,4aH)-dione→(Vinyl)magnesium bromide→1,1,2,2-Tetramethylethylene→2-Hydroxy-2-methylbutanoic acid→2-Propen-1-one→3-(3-Isopropenyl-4-methyl-3-pentenyl)-2-cyclohexen-1-one→3-Bromo-2,4-dimethylpenta-1,3-diene→3-Ethenylcyclohex-2-en-1-one→3-Ethoxy-2-cyclohexen-1-one→Aluminum trimethanide→Methylmagnesium bromide→Bromoform→Trimethyl([(3S)-3-methyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]cyclohex-1-en-1-yl]oxy)silane→(2beta,4alpha,10beta,13alpha)-10-[(Triethylsilyl)oxy](2-~2~H)taxa-5,11-diene-2,4,13-triol→(2S,3S)-2,3-Dimethyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]-2-(prop-2-enoyl)cyclohexan-1-one→(2S,3S)-3-Methyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]-2-(prop-2-enoyl)cyclohexan-1-one
(aS)-(-)-1,1'-Bi-2-naphthol→(aS)-[1,1'-Binaphthalene]-2,2'-diyl bis(trifluoromethanesulfonate)→Methylmagnesium bromide→(aS)-2,2'-Dimethyl-1,1'-binaphthalene→(aS)-4-tert-Butyl-4,5-dihydro-3H-4lambda5-dinaphtho[2,1-c:1',2'-e]phosphepine-4-thione→(aS)-(4R,4'R)-4,4'-Di-tert-butyl-4,4',5,5'-tetrahydro-3H,3'H-[3,3'-bi-4lambda5-dinaphtho[2,1-c:1',2'-e]phosphepine]-4,4'-dithione
4-Methylthiophene-2-carboxylic acid→N-Methoxy-N,4-dimethylthiophene-2-carboxamide→Bromo(methyl)magnesium→1-(4-Methylthiophen-2-yl)ethan-1-one→3-(5-Bromo-4-methylthiophen-2-yl)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazole→1-(5-Bromo-4-methylthiophen-2-yl)ethan-1-one→2,2,2-Trifluoro-1-(3,4,5-trichlorophenyl)ethan-1-one→1-(5-Bromo-4-methylthiophen-2-yl)-4,4,4-trifluoro-3-(3,4,5-trichlorophenyl)but-2-en-1-one→Amino alcohol hydrochloride→3-Methyl-5-[5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]thiophene-2-carboxylic acid→3-Methyl-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]thiophene-2-carboxylic acid→2-Amino-N-(2,2,2-trifluoroethyl)acetamide hydrochloride→5-Bromo-1,2,3-trichlorobenzene→(3,4,5-Trichlorophenyl)magnesium bromide→2,2,2-Trifluoro-N,N-dimethylacetamide
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
| 供应商 | 产品 | 价格区间 | 最小起订 | 货期 | 资质 | 操作 |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 2-bromo-3-methyl-5-acetylthiophene Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | methyl 5-acetyl-3-methylthiophene-2-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 5-acetyl-3-methyl-2-Thiophenecarboxylic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。